|
FY2025
12 months to Sep 30, 2025
|
FY2024
12 months to Sep 30, 2024
|
FY2023
12 months to Sep 30, 2023
|
FY2022
12 months to Sep 30, 2022
|
FY2021
12 months to Sep 30, 2021
|
|
|---|---|---|---|---|---|
| Expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Loss from operations | |||||
| Other income : | |||||
| Reimbursement grant income | |||||
| Interest income | |||||
| Misc other income | |||||
| Foreign exchange loss | |||||
| Nonoperating Income (Expense) | |||||
| Loss before income taxes | |||||
| Income tax expense | |||||
| Net loss | |||||
| Exchange differences on translation | |||||
| Net comprehensive loss | |||||
| Weighted average number of common shares | |||||
| Loss per common share - basic and diluted | |||||
| Weighted average number of common shares (in shares) | |||||
| Loss per common share - basic and diluted (in dollars per share) | |||||
Loading...